| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3316300 | Pancreatology | 2016 | 5 Pages |
Abstract
Patients with mPCLs exposed to immunosuppressive medications did not have higher rates of malignancy or development worrisome features in the short term. This suggests that patients with mPCLs can be initiated or maintained on these agents without changes to surveillance practices.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Amol Agarwal, Frank I. Scott, Nuzhat A. Ahmad, Vinay Chandrasekhara,